key: cord-0916600-erv7opnm authors: Hemilä, Harri; Chalker, Elizabeth title: Assessment of vitamin C effects on pneumonia and COVID-19 using Mendelian randomization: analysis may be misleading date: 2022-02-14 journal: Eur J Clin Nutr DOI: 10.1038/s41430-022-01091-9 sha: ddef3c2f3ae895311816b209ebbc5c4d20e5e3ca doc_id: 916600 cord_uid: erv7opnm nan meaningful when an examination of vitamin C and pneumonia should ideally compare plasma levels between 10-20 μM and 60-100 μM. Three small controlled trials reported significantly lower pneumonia incidence in vitamin C groups, but the contexts were very specific and thus the findings cannot be extrapolated to the general population [6, 8] . One was with school children during WW-II with documented very low vitamin C intake, another with US Marines during physically heavy recruit training, and the third with influenza A patients. In all these trials, the incidence of pneumonia in the control group was much higher than in Western countries currently [6, 8] . The three small trials have shortcomings, but nevertheless, Mendelian randomization analysis of adults in the general population is not comparable with the findings from these three trials in very specific populations. Furthermore, severe diseases such as pneumonia can decrease plasma vitamin C levels, with the decline in level correlated with disease severity [8, 9] . Hui et al. do not provide any evidence of the selected SNPs correlating with the decreased vitamin C levels of sick people. Their study does not offer any information about possible treatment effects of vitamin C for pneumonia or COVID-19, despite the claims otherwise. There are randomized trial data indicating that treatment with vitamin C may have effects on severe infections in some contexts. A re-analysis of the CITRIS-ALI trial showed that during the intervention period vitamin C reduced mortality due to sepsis by 81% (95% CI 45-94%) [10] , and a re-analysis of the COVID A to Z trial showed that vitamin C increased the rate of recovery of COVID-19 patients [11] . These treatment effects cannot be investigated using weak genetic correlations. Randomized trials are needed for conclusive evidence. The role of vitamin C in pneumonia and COVID-19 infection in adults with European ancestry: a Mendelian randomisation study Plasma vitamin C and type 2 diabetes: genome-wide association study and Mendelian randomization analysis in European populations Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance Estimated prevalence and predictors of vitamin C deficiency within UK's low-income population Serum vitamin C and the prevalence of vitamin C deficiency in the United States: 2003-2004 National Health and Nutrition Examination Survey (NHANES) Vitamin C may affect lung infections Global Vitamin C status and prevalence of deficiency: a cause for concern? Vitamin C for preventing and treating pneumonia Patients with community acquired pneumonia exhibit depleted vitamin C status and elevated oxidative stress Reanalysis of the effect of vitamin C on mortality in the CITRIS-ALI trial: important findings dismissed in the trial report Vitamin C may increase the recovery rate of outpatient cases of SARS-CoV-2 infection by 70%: reanalysis of the COVID A to Z rand omized clinical trial